These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. Comparison of Zhang Q; Zang S; Zhang C; Fu Y; Lv X; Zhang Q; Deng Y; Zhang C; Luo R; Zhao X; Wang W; Wang F; Guo H J Transl Med; 2017 Nov; 15(1):230. PubMed ID: 29115970 [TBL] [Abstract][Full Text] [Related]
16. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature. Luiting HB; van Leeuwen PJ; Busstra MB; Brabander T; van der Poel HG; Donswijk ML; Vis AN; Emmett L; Stricker PD; Roobol MJ BJU Int; 2020 Feb; 125(2):206-214. PubMed ID: 31680398 [TBL] [Abstract][Full Text] [Related]
17. In primary lymph nodal staging of patients with high-risk and intermediate-risk prostate cancer, how critical is the role of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography? Kulkarni SC; Sundaram PS; Padma S Nucl Med Commun; 2020 Feb; 41(2):139-146. PubMed ID: 31714366 [TBL] [Abstract][Full Text] [Related]
18. Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. Maurer T; Gschwend JE; Rauscher I; Souvatzoglou M; Haller B; Weirich G; Wester HJ; Heck M; Kübler H; Beer AJ; Schwaiger M; Eiber M J Urol; 2016 May; 195(5):1436-1443. PubMed ID: 26682756 [TBL] [Abstract][Full Text] [Related]